Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Aprea Therapeutics (APRE) reported operational updates via Form 8-K. The company announced the recommended Phase 2 dosing for ATRN-119, paused further enrollment in both once-daily and twice-daily dosing arms of ABOYA-119, and is considering additional ATRN-119 development in combination therapies.
The updates were communicated in a press release dated October 15, 2025, and accompanied by a refreshed corporate presentation. Both materials are provided as exhibits to the filing, offering more detail on current development plans and clinical program status.
Aprea Therapeutics, Inc. filed a Form 8-K to report that it updated its corporate presentation slide deck on September 8, 2025. The updated investor presentation, dated September 2025, is included as Exhibit 99.1 and incorporated by reference. This is a routine corporate communication intended to provide updated information about the company to investors and other stakeholders.
Sio Capital Management, LLC reports beneficial ownership of 279,369 shares of Aprea Therapeutics common stock, representing 5.05% of the class as of June 30, 2025. The position is held for affiliated funds for which Sio is the registered investment adviser; Sio reports 0 sole voting or dispositive power and 279,369 shared voting and dispositive power.
The 5.05% figure is calculated using 5,525,172 shares outstanding as of April 22, 2025. The filing notes that the general partner and Michael Castor may be deemed to have influence over the accounts that own the shares, while expressly disclaiming beneficial ownership; the filer certifies the shares are held in the ordinary course of business and not to change or influence control.
Aprea Therapeutics reported cash and cash equivalents of $16.5 million and total assets of $17.3 million, with an accumulated deficit of $328.2 million. The company recorded a net loss of $7.17 million for the six months and used $6.8 million of cash in operating activities over the same period. Grant revenue declined to $0.28 million year-to-date, largely from reduced NIH funding. Research and development spending was $4.40 million for six months, driven by ATRN-119 and APR-1051 programs, and the company expects safety/efficacy data in the second half of the year with RP2D decisions expected in the first half of 2026. Management states existing cash is not sufficient to fund operations for at least twelve months and has concluded substantial doubt exists about its ability to continue as a going concern, and is seeking additional funding.
Aprea Therapeutics furnished a press release that announces its financial results for the three- and six-month periods ended June 30, 2025 and provided an operational update. The press release is attached as Exhibit 99.1 and the company also updated its corporate presentation, filed as Exhibit 99.2. The Form 8-K states that the information in Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
The 8-K itself does not include the underlying financial figures or metrics; it notifies investors that the detailed results and presentation materials are available in the referenced exhibits.